SCOTTSDALE, Ariz., May 20 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today the formation of a Scientific Advisory Board. The Board's purpose is to guide advanced scientific investigations into the mechanism of action of Provant, new product development, and further application of Regenesis' platform technology to clinical and industrial applications.
"This is another milestone in Regenesis' strategic plan to advance the science of wound care," said Virginia Rybski, Acting President of Regenesis. "Our Scientific Advisory Board is composed of academics and thought leaders who are experts in the field of bioelectrochemistry, which is the interaction between energy and living systems. This group will assist in our evidenced- based decision-making as we further expand our platform technology into next generation products."
The Regenesis Scientific Advisory Board brings together experts recognized in their fields:
About the Provant Wound Therapy System
Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues. We believe Provant is effective, economical, and easy-to-use.
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long- term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.
CONTACT: Media, Scott Robey, VP Marketing, firstname.lastname@example.org,
Clinicians, Rick Isenberg, MD, VP Clinical Affairs,
email@example.com, or Investors, Virginia Rybski, Acting
President, firstname.lastname@example.org, all of Regenesis Biomedical,
Web site: http://www.regenesisbiomedical.com//